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Since the pioneering work of Hayashi (1944; English publication 1952) , it has been known that glutamate plays a prominent role in epileptic phenomena. Ion channels regulating glutamatergic and GABAergic synaptic transmission provide the dominant control over central nervous system excitability and therefore play a large role in the initiation and suppression of epileptic phenomena and represent the molecular substrate for a predominant number of currently used antiepileptic drugs (AEDs). AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors regulate fast excitatory neurotransmission in the mammalian nervous system and have been a target of AED discovery and development for many years. Additionally, data from genetic studies (Lerche et al., 2013) as well as AMPA receptor upregulation in brains from epileptic patients (Palomero-Gallagher et al., 2012) , have added additional rationale for targeting AMPA receptors in the control of epilespy.
Multiple structurally-distinct AMPA receptor antagonists, including competitive and non-competitive blockers, have been shown to possess potent and efficacious activity in a range of in vitro and in vivo models detecting AED efficacy (Rektor, 2013; Rogawski, 2011 Rogawski, , 2013 Russo et al., 2012) . A few of these molecules have been investigated in humans for their antiepileptic potential. The AMPA receptor antagonist talampanel (GYKI 53773; LY300164) was shown to produce significant reduction in seizure frequency with dizziness (52%) and ataxia (26%) being the only adverse events reported (Chappell et al., 2002) . Final proof of concept that AMPA receptor antagonism can serve as an antiepileptic control of refractory partial seizures came with the approval of the non-competitive antagonist, perampanel (Fycompa®; Fig. 1) , which is the first selective AMPA receptor antagonist on the market.
Perampanel has demonstrated efficacy in multiple preclinical models that helped inform drug development for epilepsy (Hanada et al., 2011; Hibi et al., 2012; Rogawski and Hanada, 2013) . Perampanel has been investigated in several Phase III clinical studies (French et al., 2012; Rektor et al., 2012; Krauss et al., 2012 Krauss et al., , 2013 . The key clinical trials were conducted on a global level as randomized, double-blind, placebocontrolled, dose-escalation studies that examined 1,480 patients with partial-onset seizures. These studies demonstrated that perampanel as an adjunctive therapy significantly reduced seizure frequency in patients with partial-onset seizures with or without secondary generalized seizures (see reviews and analysis by Gao et al., 2013; Rheims and Ryvlin, 2013; Steinhoff et al., 2013; Zaccara et al., 2013) . Fycompa® was approved (October, 2012) by the U.S. FDA for use as an adjunctive treatment of partialonset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. However, as observed with talampanel, perampanel also engenders a range of side effects predicted from both its mechanism of action and preclinical data that include dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder, gait disturbance, vertigo, and weight gain. Nonetheless, at efficacious dosages, perampanel is generally well tolerated.
AMPA receptors are widely expressed in the central nervous system. There are four different AMPA receptor subunits (GLK A1-4 ) and these subunits are broadly, albeit differentially, expressed in the brain. The subunit selectivity of perampanel among AMPA receptor isoforms is not known (Rogawski and Hanada, 2013) . Since perampanel causes beneficial as well as side effects, we presume that perampanel inhibits AMPA receptors broadly across the brain regardless of their subunit composition. Our hypothesis This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 15, 2014 as DOI: 10.1124 at ASPET Journals on October 19, 2017 jpet.aspetjournals.org Downloaded from is that the beneficial effects of perampanel are mediated by AMPA receptors in brain regions related to epilepsy (cerebral cortex, hippocampus, amygdala, thalamus) and that some of the side effects are caused by inhibiting AMPA receptors in other brain regions.
The cerebellum is likely to play a role in some of the side effects observed with parampanel (dizziness, falls, nausea, ataxia, balance disorder and vertigo) based upon the known physiological regulation of these clinical signs by the cerebellum (Della-Morte and Rundek, 2012; Salman, 2002 ). The hypothesis was tested with novel electrophysiological techniques to study the sensitivity to perampanel of AMPA receptors from different brain areas of both rat and human. In addition, since epileptic brain tissue has shown changes in AMPA receptor density (c.f., Brines et al., 1997; PalomeroGallagher et al., 2012) , we also evaluated the effects of perampanel in human epileptic brains.
In particular, we adopted a recently developed technique (Miledi et al., 2006; Eusebi et al., 2009 ) based on the reconstitution of native human neurotransmitter receptors into oocytes of the African clawed toad (Xenopus laevis), followed by voltageclamp recording. The strength of this technique is that it can be applied to post-mortem frozen human brain samples as well as freshly-excised tissue. The technique can also be used to study native ion channels from diseased brain. For example, it has been applied to study differences in native human GABA A receptors between control and epileptic human hippocampi (Palma et al., 2005; Palma et al., 2007) .
Finally we examined the effects of perampanel directly on fresh cortical slices obtained from the same epileptic patient studied in oocytes, but this time utilizing a 60 microelectrode recording array (Hobbs et al., 2010 23-31g were used. Animals were maintained in the colony room for at least 3 days before testing. Animals were moved to a quiet room 1 hour prior to the start of the test.
All studies were performed according to the guidelines set forth by the National Institutes Electroshock. Mice (n=10/dose) were used with Wahlquist Model H stimulator with 0.2 sec stimulation with corneal electrodes. Mice were observed for approximately 10 sec after administration of the electrical stimulus (10uA) and the types of convulsions were recorded (0 = no convulsion, 1 = clonus, 2 = tonic flexion, 3 = tonic extension).
Mice were euthanized immediately following test. Only one mouse was used per treatment. Tonic extension was used as the primary endpoint for calculation of ED 50 values.
Inverted Screen Test. Prior to dosing rats or mice with PTZ, the animals were tested (30 min post drug administration) on an inverted screen. The apparatus is made of six 11cm x 14 cm (mouse) or four 13cm x 16 cm squares (rat) of round hole, perforated This article has not been copyedited and formatted. The final version may differ from this version. For mice, on the day prior to test, mice are placed on the screen and the rod is rotated 180° over 2-3 seconds. The amount of time it takes for the test subject to climb to the top of the screen is recorded. For test subjects that hang on the bottom for the maximum of 60 sec, a 60 sec score is recorded. Test with compound on board is studied the following day in the same manner.
For rat studies, animals were dosed with test compound, po, and returned to their home cage. Twenty five min after pre-treatment, animals were tested on the inverted screen and were scored after 60 seconds as follows: (0=climbed over, 1= hanging on to screen, 2= fell off). After the inverted screen test, animals were dosed with pentylenetetrazol (PTZ) in a volume of 1 ml/kg and placed in an observation cage (40.6x20.3x15.2 cm) with a floor containing 0.25 inches of wood chip bedding material. Twelve fully kindled rats were assigned to this study and eight rats were selected and randomized to initial compound treatment groups from baseline after discharge threshold (ADT), seizure severity score, and after discharge duration (ADD). A pseudo within-subjects Latin Square design was used for subsequent testing, as replacement rats were used in the event that an assigned rat did not meet the pre-compound testing baseline criteria or a rat lost it head cap during a seizure. On test day rats were dosed 30 min prior to beginning stimulation. After the pre-treatment, rats were stimulated using an ascending staircase sequence beginning at 10µA and increasing in log unit steps of 10, 16, 25, 40, 65, 100, 160, 250, and 400μA . Animals were stimulated until they were assigned a Seizure Severity Score for a visually observably seizure or they reached the 400μA threshold limit. ADD was determined following testing. ADT was the current that induced a scoreable seizure. Seizure Severity: Racine score of behavioral response to stimulation: 0 = no behavioral response; 1 = immobility, staring and/or facial clonus; 2 = head nodding, jaw clonus, and/or tongue protrusion; 3 = unilateral forelimb clonus; 4 = bilateral forelimb clonus and/or rearing; 5 = bilateral forelimb clonus with rearing and loss of balance. After-Discharge Duration (ADD) is the duration of the first afterdischarge.
Statistics anaylsis. ADT, ADD, and seizure severity scores were recorded for each animal. Data was analyzed by ANOVA and post-hoc Dunnett's t-test. Statistical analyses were performed using JMP statistical software (SAS Institute Inc., Cary, NC).
A probability of p ≤ 0.05 was used as the level of statistical significance. Lacosamide was diluted from a stock solution of 10 mg/ml with saline (0.9% NaCl) and dosed in a volume of 1 or 3 ml/kg for rat (dosed via IP route, 30 min prior to testing) and a volume of 10 ml/kg was used for mice (dosed via IP route, 30 min prior to testing).
Diazepam was dissolved in 20% 2-hyroxypropyl-beta-cyclodextrin in water. Diazepam was administered in a volume of 1 ml/kg for rat (dosed via IP route, 30 min prior to testing and a volume of 10 ml/kg was used for mice (dosed via IP route, 30 min prior to testing). Valproic acid was dissolved in saline and administered in a volume of 4 ml/kg to rats via IP route, 30 min prior to testing and dosed as the acid form.
Xenopus Oocyte Studies: Effects on human and rat hippocampal and cerebellar

AMPA receptors reconstituted into Xenopus oocytes.
Rat hippocampal and cerebellar brain samples were taken from 2-3 months old Membrane preparations from these tissues were prepared according to the method developed and described by Miledi et al. (2006) and Eusebi et al. (2009) . In short: 0.1 -0.5 g of fresh rat tissue or of frozen human tissue was homogenized in ice-cold glycine buffer (in mM: 200 glycine, 150 NaCl, 50 EGTA, 50 EDTA, 300 sucrose) to which 10 μl protease inhibitor cocktail (Sigma) was added per ml glycine buffer. The homogenate was centrifuged at 4°C for 15 min at 9500 g. The supernatant was subsequently centrifuged at 4°C for 2 hrs at 100,000 g with an ultra-centrifuge and the pellet was resuspended in ice-cold assay buffer (5 mM glycine). The protein concentration of the membrane preparations were measured using the Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, U.S.A.) and were between 2.5 and 7 mg/ml. Aliquots of the suspensions were kept at -80°C and were thawed just before injection into Xenopus oocytes.
Xenopus oocytes (stage V-VI) were removed from schedule I sacrificed frogs and defolliculated after treatment with collagenase type I (5 mg/ml calcium-free Barth's solution) for 1.5. h at room temperature. 60 nl of membrane suspension was injected per oocyte using a Drummond (Broomall, PA, U.S.A.) variable volume microinjector. After injection, oocytes were incubated at 18°C in a modified Barth's solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 0.3 mM Ca(NO 3 ) 2 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 , 15 mM HEPES and 50 mg/l neomycin (pH 7.6 with NaOH; osmolarity 235 mOsm). Experiments were performed on oocytes after 2-5 days of incubation.
Oocytes were placed in a recording chamber (internal diameter 3 mm), which was continuously perfused with a saline solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM according to the methods described by Stühmer (1998) . The external saline was clamped at ground potential by means of a virtual ground circuit using an Ag/AgCl reference electrode and a Pt/Ir current-passing electrode. The membrane potential was held at -60 mV. The current needed to keep the oocyte's membrane at the holding potential was measured. Membrane currents were low-pass filtered (four-pole low-pass Bessel filter, -3 dB at 10 Hz), digitized (50 Hz), and stored on disc for offline computer analysis. Data are expressed as mean ± s.e.m. All experiments were performed at room temperature.
For antagonist concentration-inhibition curves, ion currents were evoked by switching from control solution to a solution containing 100 μM AMPA and 100 μM cyclothiazide (CTZ). After 30 s of AMPA/CTZ perfusion the solution was switched to AMPA/CTZ plus various concentrations of perampanel for 20 s. The amount of inhibition was calculated from the current amplitude at the end of perampanel application and the current amplitude of the AMPA/CTZ response just before perampanel application. Concentration-inhibition curves were fitted according to the Hill equation.
Curve fitting was performed using Graphpad Prism 3.01 software (San Diego, CA,
U.S.A.).
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Tissue preparation and recording:
The block of tissue from the patient describe above was then sliced into coronal sections with a thickness of 250 µm using a vibratome tissue slicer. Coronal sections were cut using white matter as landmark. After cutting, slices were bathed for ~1hr at room temperature in ACSF with the same ingredients as listed above, but with 125 mM NaCl substituted for 125 mM sucrose to restore Na + and allow cells to fire action potentials again.
In preparation for recording, slices were adhered to microelectrode arrays (MEA;
Multichannel Systems, Reutlingen, Germany) with a solution of 0.1% polyethelinamine that had been previously applied and let to dry for 2 hrs (Wirth and Luscher, 2004) . We attempted to place the tissue so that neocortical layers I-V covered the array. Slices were maintained thermostatically at 37° C and were perfused at 1.0 ml/min first with normal . These external ionic concentrations are known to produce robust local field potential (LFP) activity in cortical brain slices (Schiff et al., 1994; Wu et al., 1999 and verified Local field potential (LFP) detection. Extracellular activity from slices was recorded in the same manner as previously reported (Tang et al., 2008) . Activity was sampled from all 60 electrodes (Fig. 3B ) at 1 kHz and amplified before being stored to disk for offline analysis. Local field potentials (LFPs) that showed sharp negative peaks below a threshold set at 3 standard deviations of the signal were marked, and the time of the maximum excursion was recorded as the time of that LFP. Time points were binned at 4 ms resolution, as this was previously shown to match the average time between successive LFP events across electrodes (Beggs and Plenz, 2003) .
In characterizing network activity, we closely followed the methods first described in (Beggs & Plenz, 2003 ). An avalanche is a sequence of consecutively active frames that is preceded by a blank frame and terminated by a blank frame. The length of an avalanche is given by the total number of active frames and the size of an avalanche is given by the total number of electrodes activated during the avalanche.
Measuring the branching parameter. The branching parameter, symbolized by σ , is the average number of descendant electrodes produced by a single ancestor electrode.
By ancestor electrode, we mean an electrode on the array that experienced a suprathreshold LFP signal at a given time step. By descendant electrode, we mean an electrode on the array that experienced a supra-threshold LFP signal one time step after the activity This article has not been copyedited and formatted. The final version may differ from this version. of the ancestor electrode. The branching parameter is straightforward to approximate from experimental data, and can be obtained by taking the parameter:
where L is the length of each avalanche, N2:L is the total number of electrodes activated in frames 2 to L, N1:(L-1) is the total number of electrodes activated in frames 1 to L-1, and the angled brackets indicate averaging over all avalanches. From this definition, it is clear that the branching parameter is a measure of collective excitability in the network.
Intuitively, when σ < 1, activity is damped and will quickly die out. When σ = 1, the network is in the critical state and long chains of neural activity can occur without unstable expansion. When σ > 1, activity is amplified every time step, eventually leading to excessive network activity. Excessive network activity can be induced by washing the slice in 10 uM of pictrotoxin. This increase in network activity can mimic a seizure state in the slice. Once an excited state is induced, the effects that perampanel has on network activity can be measured by the branching parameter as just described.
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Pentylenetetrazole (PTZ)-Induced Seizures. Both perampanel and lacosamide
were fully effective in attenuating PTZ-induced clonic seizures in both mice and rats.
The potencies of these drugs under these assays are shown in Table 1 . Amygdala Kindling. In amaygdala kindled rats, perampanel and lacosamide were studied after doses of 3-30 mg/kg, p.o. Under these conditions, perampanel was efficacious in dampening all measured parameters of seizure kindling at 30 mg/kg except the after discharge duration which was also unaffected by lacosamide ( Table 1) .
Pentylenetetrazole (PTZ)-Induced
Although lacosamide was ½-log dose more potent in protecting against after-discharge This article has not been copyedited and formatted. The final version may differ from this version. Effects on native human and rat hippocampal and cerebellar AMPA receptors reconstituted into Xenopus oocytes.
Oocytes injected with membranes from rat or human hippocampal or cerebellar membranes did not respond to 100 μM AMPA with measurable currents (not shown), but when 100 μM AMPA was co-applied with 100 μM of the AMPA receptor potentiator cyclothiazide (CTZ), AMPA receptor-mediated ion currents were clearly observed, which were almost completely inhibited when 30 μM perampanel was applied during the AMPA/CTZ response ( Fig. 2A) . Perampanel induced concentration-dependent inhibition of AMPA/CTZ (Fig. 2B) . The IC 50 and Hill-slope values are shown in demonstrate that perampanel inhibited native rat and human hippocampal and cerebellar AMPA receptors with similar potency and to the same extent.
Membranes were also prepared from the hippocampal tissue obtained from the epileptic patient and further injected into oocytes. Also in this case perampanel produced a concentration-dependent blockade of ion currents evoked by application of AMPA/CTZ (Fig. 3) with an IC 50 of 6.7 μM, demonstrating that perampanel is indeed blocking AMPA receptors in the diseased brain.
Human Epileptic Cerebral Cortex Electrophysiology.
Characterizing multi-electrode activity. In characterizing network activity, we closely followed the methods first described in (Beggs & Plenz, 2003 and illustrated in figure 4 . The configuration of active electrodes during one time step is called a frame.
An avalanche is a sequence of consecutively active frames that is preceded by a blank frame and terminated by a blank frame. The length of an avalanche is given by the total number of active frames and the size of an avalanche is given by the total number of electrodes activated during the avalanche.
Spontaneous activity in human slices. As reported previously human slices are rarely active in NACSF (Hobbs et al. 2010) . This was also true in this experiment, and in order to test the effects of perampanel in this experiment, the slice was bathed in 10 μM of picrotoxin, elevated K + and reduced Mg 2+ + . This concentration was found to evoke large field potentials on at least 45 channels of the array.
This article has not been copyedited and formatted. The final version may differ from this version. that exceeded the threshold on multiple electrodes in the same time bin. We also observed cascades of consecutively active time bins (Fig. 4) . After cascades were recorded over 45 minutes or more, it was possible to plot their size distribution. We previously reported that in data collected from rats, this size distribution had a very long tail that approached a power law (Tang, et al 2008) . This distribution was not expected by chance (Beggs, 2008) , but was similar to that produced by computational models of sand pile avalanches (Bak, 1996) .
Perampanel effects on epileptic human brain tissue.
We first recorded the slice activity for 1 hr in 10μM of Picrotoxin to establish a base line. The average amplitude was -23.34 + 7.07 μV and the average firing rate (Fig. 5A) was 0.14 + 0.02 Hz during this recording. In the second hour of recording, 10μM of perampanel was added along with the 10μM of Picrotoxin. The amplitude showed a trend toward a decrease as shown in Fig. 6A to -21.22 + 5.24 μV and the average firing rate decreased to 0.06 + 0.01 Hz (Fig. 5A) . Both of these decreases were statistically significant (p< 0.05, paired test).
This decrease in activity was maintained after washout with 10μM picrotoxin -19.68 + 8.57 μV; and 0.06 + 0.01 Hz (N3 reference table 1). Statistically significant decreases in both amplitude and firing rate establish that perampanel decreases activity in the slice from a human epileptic patient. Epilepsy is a network phenomenon; groups of neurons exhibiting abnormal electrical activity. Understanding epilepsy thus requires scrutiny of the activation of groups of neurons at the network level. In order to establish the effects of perampanel at the network level, we measured the branching ratio (as discussed in the methods section).
This article has not been copyedited and formatted. The final version may differ from this version. Branching Parameter. As previously mentioned in the methods section, 10 μM picrotoxin was washed into the slice bath to induce excitability in the slice network.
After recording this picrotoxin induced excitability for 1 hour, 10 μM perampanel was washed into the slice bath while maintaining the 10 μM picrotoxin solution. The perampanel at 10 μM significantly decreased the branching ratio in the network (as data are non-normally distributed we use the Kolmogorov Smirnov paired t-test at p< 0.05).
In figure 6 , the tissue in 10 μM of pictrotoxin had an average branching parameter of 
Discussion
In the present study we document that in rodent models, seizures in both rats and mice were well controlled by perampanel. Previous preclinical reports have documented efficacy for perampanel against seizures in rodents (Hanada et al., 2011; Rogawski and Hanada, 2013) . In these studies, perampanel attenuated audiogenic, electroshockinduced, PTZ-induced seizures, 6 Hz-driven seizures and amygdala kindled-seizures in rodents (Hanada et al., 2011) . The present findings provide the first systematic replication of the preclinical findings from Eisai Corporation (Hanada et al., 2011 ) that markets perampanel. The translational value of these data are documented in the correspondence in the efficacy in rodents and the antiepileptic efficacy in epileptic patients with partial-onset seizures with or without secondary generalized seizures (see reviews and analysis by Gao et al., 2013; Rheims and Ryvlin, 2013; Steinhoff et al., 2013; Zaccara et al., 2013) .
In addition to anticonvulsant protection in rodents, perampanel induced motor deficits on the inverted screen test in mice and rats. The potencies for inducing motor impairments were greater than that for efficacy as an anticonvulsant with the exception of mouse electroshock seizures where a protective index of > 1 was found (3.5). Low dose margins of efficacy over motor effects have been reported before in rodents (Hanada et. al., 2011) . Although well tolerated, perampanel has shown motor impairments in human studies and in Phase 3 data (French et al., 2012; Rektor et al., 2012; Krauss et al., 2012 Krauss et al., , 2013 . Thus, although protective indicies in rodents are not always fully translatable into human motor side-effect liabilities (Löscher and Nolting, 1999) , the data with Some aspects of the fresh brain slice experiments are worth considering in more detail. Our data extend previous findings obtained with perampanel in cultured cortical neurons (Hanada et al., 2011) and studying synaptic transmission in hippocampal slice preparations of rat brain (Ceolin et al., 2012) . As previously reported, tissue from humans is rarely spontaneously active in vitro (Hobbs et al. 2010) . Picrotoxin acts as a noncompetitive antagonist for GABA A receptor chloride channels, and is well known for This article has not been copyedited and formatted. The final version may differ from this version. increasing excitability in neural tissue (Mackenzie et al 2002) and was used to investigate the effects of perampanel. The results from these in vitro studies, consistently with the Phase III efficacy data,show that perampanel provides seizure protection in cortical slices from the active region of the left temporal lobe from a medication-unresolved epilepsy patient. Perampanel significantly dampened local population activity and network activity in human tissue from an epileptic patient. This conclusion was derived from three specific measures: firing rate, amplitude, and the branching parameter, all of which decreased when 10μM of perampanel was washed into the slice bath.
Although these results are statistically significant, caution must be exercised when extrapolating these findings to human tissue in vivo. Experiments with slices are limited by several factors. Long-range neuronal connections are severed and severing these long-range connections alters network properties, and activity in the network failed to recover and return to baseline after perampanel was washed out. As obtaining human tissue is rare, this study relies on a sample of one, and replication is warranted. Finally, in a previous publication (Hobbs et al. 2010) we showed that large network-wide events occurred simultaneously for extended periods of time in some tissue from human patients with epilepsy, and that the branching parameter was positively correlated with firing rate in these recordings. We also showed that this "seizure-like" activation can drive down the branching parameter (Hobbs et al. 2010) as the descendant of an extended networkwide event can at most have the same size, or more likely fewer branches than its ancestor. In order to confirm that the effects on the branching parameter were not derived from network-wide activation, we searched for sustained network-wide events on This article has not been copyedited and formatted. The final version may differ from this version. Finally, it is crucial to understand the source of perampanel's side effects, in order to be able to develop AEDs with better margins of safety. Given the motor impairments observed in rodents (Hanada et al., 2011; Rogawsky and Hanada, 2013; present study) and the ataxia and dizziness reported in epileptic patients at higher doses of perampanel (French et al., 2012; Rektor et al., 2012; Krauss et al., 2012 Krauss et al., , 2013 (Menuz et al., 2007; Cokic and Stein, 2008; Kato et al., 2010) . It is currently not know if the activity of perampanel is influenced by TARPs. TARP γ2 is highly expressed in the cerebellum (Tomita et al., 2003) . Thus, an AMPA receptor antagonist that has reduced potency and/or efficacy at AMPA receptors associated with TARP-γ2
This article has not been copyedited and formatted. The final version may differ from this version. relative to other AMPA receptor isoforms might provide antiepileptic control without the cerebellar-mediated motor side effects.
In conclusion, our experimental findings confirm our hypothesis that peramapel antagonizes AMPA currents in both brain areas responsible for epileptic discharge and brain areas controlling motoric side-effects. These experimental data in rodent and human tissue are consistent with the antiepileptic and motoric profile of perampanel in patients with refractory partial seizures. These data add to the growing body of data implicating that dampening of excitatory neurotransmission through AMPA receptors is a safe and effective means of seizure control. The introduction of perampanel (Fycompa) to the clinic will enable the opportunity for the first time to evaluate this mechanism compared to others in epilepsy therapeutics.
